Literature DB >> 19515020

Tumor necrosis factor-alpha-stimulated membrane type 1-matrix metalloproteinase production is modulated by epidermal growth factor receptor signaling in human gingival fibroblasts.

P C Smith1, J Guerrero, N Tobar, M Cáceres, M J González, J Martínez.   

Abstract

BACKGROUND AND OBJECTIVES: Membrane type 1-matrix metalloproteinase (MT1-MMP) is a collagenolytic enzyme involved in connective tissue remodeling. In periodontal tissues, either cytokines or growth factors regulate the production of proteolytic enzymes. Mice deficient in epidermal growth factor receptor (EGFR) show a reduced expression of MT1-MMP, suggesting that this receptor may play an important role in MT1-MMP production. The present study evaluated the role of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and EGFR in the production of MT1-MMP in gingival fibroblasts.
MATERIAL AND METHODS: Primary cultures of human gingival fibroblasts were cultured over plastic or a type I collagen matrix and stimulated with TNF-alpha and EGF. A selective EGFR inhibitor (AG1478) was used to interfere with this signaling pathway. Production of MT1-MMP and activation of proMMP-2 were studied using Western blot and gelatin zymography, respectively. Activation of EGFR signaling was assessed through immunoprecipitation and Western blot. Expression of EGFR ligands was determined through reverse transcriptase-polymerase chain reaction.
RESULTS: Treatment of gingival fibroblasts cultured over a collagen matrix with TNF-alpha stimulated proMMP-2 activation and MT1-MMP production. However, after using AG1478, both responses were inhibited. Tumor necrosis factor-alpha induced EGFR transactivation and stimulated the expression of the mRNA for the EGFR ligands heparin binding-epidermal growth factor (HB-EGF) and transforming growth factor-alpha (TGF-alpha).
CONCLUSIONS: The present study shows that TNF-alpha may stimulate MT1-MMP production through transactivation of EGFR. Tumor necrosis factor-alpha may also modulate the expression of the EGFR ligands TGF-alpha and HB-EGF. Production of MT1-MMP by TNF-alpha requires interaction with EGFR, suggesting that tissue remodeling is controlled by cross-communication between diverse signaling pathways in gingival fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515020     DOI: 10.1111/j.1600-0765.2007.01081.x

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  5 in total

1.  A.actinomycetemcomitans-induced periodontal disease promotes systemic and local responses in rat periodontium.

Authors:  Beatriz de Brito Bezerra; Oelisoa Andriankaja; Jun Kang; Sandra Pacios; Hyung Jin Bae; Yu Li; Vincent Tsiagbe; Helen Schreiner; Daniel H Fine; Dana T Graves
Journal:  J Clin Periodontol       Date:  2012-02-07       Impact factor: 8.728

2.  The epidermal growth factor receptor mediates tumor necrosis factor-alpha-induced activation of the ERK/GEF-H1/RhoA pathway in tubular epithelium.

Authors:  Eli Kakiashvili; Qinghong Dan; Matthew Vandermeer; Yuqian Zhang; Faiza Waheed; Monica Pham; Katalin Szászi
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

3.  Pathological role of excessive DNA as a trigger of keratinocyte proliferation in psoriasis.

Authors:  Y Luo; T Hara; A Kawashima; Y Ishido; S Suzuki; N Ishii; T Kambara; K Suzuki
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

4.  Autocrine IL-1β-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFα signalling to carcinoma-associated fibroblasts.

Authors:  S I Chaudhry; S Hooper; E Nye; P Williamson; K Harrington; E Sahai
Journal:  Oncogene       Date:  2012-03-26       Impact factor: 9.867

5.  Accelerated wound closure in vitro by fibroblasts from a subgroup of cleft lip/palate patients: role of transforming growth factor-α.

Authors:  Joël Beyeler; Isabelle Schnyder; Christos Katsaros; Matthias Chiquet
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.